Macquarie Group LTD Supernus Pharmaceuticals, Inc. Transaction History
Macquarie Group LTD
- $80.3 Billion
- Q1 2025
A detailed history of Macquarie Group LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 2,699,667 shares of SUPN stock, worth $90.7 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,699,667
Previous 2,628,907
2.69%
Holding current value
$90.7 Million
Previous $95.1 Million
6.99%
% of portfolio
0.11%
Previous 0.11%
Shares
31 transactions
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.7MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$349 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$207 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$175 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$97.5 Million0.02% of portfolio
-
State Street Corp Boston, MA2.15MShares$72.1 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.8B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...